MedTrace Logo

Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Treatment

NCT00674141 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2010-06-03

No results posted yet for this study

Summary

The study aims to assess the safety and efficacy of nasale administration of Dexamethasone in relapsing MS patients

Conditions

  • MS Patient With Relpasing Remitting Attacks

Interventions

DRUG

Dexamethasone soduim phosphate

nasale administation of Dexamethasone in 20mg dose/day (in two divided doses) fpr sevem days of treatment

Sponsors & Collaborators

  • Hadassah Medical Organization

    lead OTHER

Principal Investigators

  • Elka Touitou, PhD, Prof. · Hebrew University, Jerusalem. Israel

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2008-12-31
Completion
2009-01-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00674141 on ClinicalTrials.gov